NCT07447791 WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients
| NCT ID | NCT07447791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guy's and St Thomas' NHS Foundation Trust |
| Condition | Acute Kidney Injury (Nontraumatic) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-02-15 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-02-15 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury is a potentially life threatening condition which affects 1 in 2 patients in the Intensive Care Unit (ICU). Patients often need dialysis treatment, also called renal replacement therapy. Renal replacement therapy is a treatment that removes toxins and excess fluid from the blood stream. It consists of having a small plastic catheter in a vein in the neck or in the groin through which blood flows through a dialysis machine and is cleansed and excess water is removed. The cleansed blood is then returned to the patient via the same catheter. One of the major areas of uncertainty for doctors in the ICU is "What is the right intensity of renal replacement therapy for patients with acute kidney injury?" A higher intensity indeed removes more toxins but also removes other substances in the blood, including vitamins, nutrients and important medications. The current usual dose is around 25 ml/kg/hr but clinical practice in the UK is very variable and some patients routinely receive higher doses and some get lower doses. Data from large databases worldwide have suggested that a lower dose is safe and effective and may potentially allow the kidneys to recover faster but confirmation is lacking. In this study, the investigators investigate whether renal replacement therapy at a lower intensity is as effective and safe as currently used doses. Participants will be randomised to receiving renal replacement therapy at usual or lower intensity. There will be no change to any other aspects of treatment. The results will inform the investigators whether the study protocol is feasible and how best to design a future larger research study.
Eligibility Criteria
Inclusion Criteria: * age ≥ 18 years * patient weight ≥ 55 kg * plan to start CRRT or within 24 hours of having started CRRT for AKI * expected to survive and receive CRRT for a duration of ≥ 48 hours Exclusion Criteria: * indication for sustained higher dose-intensity CRRT * end-stage kidney disease receiving maintenance dialysis * previous receipt of RRT for AKI during the current hospitalization * inability to comply with the requirements of the study protocol
Contact & Investigator
Gillian Radcliffe
STUDY CHAIR
Guy's & St. Thomas Hospital
Frequently Asked Questions
Who can join the NCT07447791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury (Nontraumatic). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07447791 currently recruiting?
Yes, NCT07447791 is actively recruiting participants. Contact the research team at m.ostermann@nhs.net for enrollment information.
Where is the NCT07447791 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07447791 clinical trial?
NCT07447791 is sponsored by Guy's and St Thomas' NHS Foundation Trust. The principal investigator is Gillian Radcliffe at Guy's & St. Thomas Hospital. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.